Covid-19 Vaccine Development Is Less Vaxart, More Science

Total Page：16

File Type：pdf, Size：1020Kb

February 04, 2021 Covid-19 vaccine development is less Vaxart, more science Madeleine Armstrong With phase III Covid-19 vaccine data coming thick and fast it is sometimes easy to forget that there is still a host of candidates in early development. One of those, Vaxart’s VXA-CoV2-1, looks like it might not be around for much longer, however, after disappointing data reported yesterday. A phase I study of the oral project failed to find neutralising antibodies in subjects’ serum, and most participants did not have an IgG response. But Vaxart has not given up: the company highlighted T-cell responses and said it would now broaden its Covid-19 vaccine development plans. The developer had hoped that, by including both the spike and N proteins, VXA-CoV2-1 could protect against new coronavirus variants. And, with many of the projects listed below beginning development before new variants emerged, the relevance of the remaining early pipeline might now be limited. The exceptions could come from Gritstone, which last month said it would soon take a more broadly acting candidate into phase I; and Curevac and Glaxosmithkline, which yesterday agreed to collaborate on next-gen mRNA projects, including a multivalent vaccine to address emerging variants. Click here for our look at the mid/late-stage Covid-19 vaccine pipeline. The third wave of Covid-19 vaccine candidates Project Description Company Update VXA-CoV2-1 Oral adenovirus type 5 vaccine Vaxart (US) Ph1 data disappoint VLA2001 Inactivated virus Valneva (France) Ph1/2 data due April 2021 AG0301- Data from Japan study due DNA vaccine Anges (Japan) COVID19 Q1'21 GX-19 DNA vaccine Genexine (S. Korea) Ph1 started Jul 2020 LNP- Self-amplifying RNA vaccine Imperial College (UK) P1 started Jun 2020 nCoVsaRNA Covax19 Recombinant protein vaccine Vaxine (Australia) Ph1 started Jun 2020 GRAd-COV2 Gorilla adenovirus vaccine Reithera (Italy) P1 ongoing Self-amplifying RNA + Gritstone Oncology/Genevant NIH-sponsored Ph1 to start Unnamed adenoviral vaccine (US) Q1'21 Curevac/Glaxosmithkline Development to begin Unnamed Next-gen mRNA vaccine (Germany/UK) "immediately" List not exhaustive. Source: EvaluatePharma & company statements. More from Evaluate Vantage Evaluate HQ 44-(0)20-7377-0800 Evaluate Americas +1-617-573-9450 Evaluate APAC +81-(0)80-1164-4754 © Copyright 2021 Evaluate Ltd..

Copy Link

Recommended publications

Immunogenicity of Clinically Relevant SARS-Cov-2 Vaccines
Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 1 Immunogenicity of clinically relevant SARS-CoV-2 vaccines in non-human primates and humans P. J. Klasse (1,*), Douglas F. Nixon (2,*) and John P. Moore (1,+) 1 Department of Microbiology and Immunology; 2 Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 *These authors contributed equally +Correspondence: [email protected] Short title: SARS-CoV-2 vaccine immunogenicity Key words: SARS-CoV-2, S-protein, RBD, COVID-19, neutralizing antibodies, serology, T- cells, vaccines, animal models, Operation Warp Speed © 2020 by the author(s). Distributed under a Creative Commons CC BY license. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 2 Abstract Multiple preventive vaccines are being developed to counter the COVID-19 pandemic. The leading candidates have now been evaluated in non-human primates (NHPs) and human Phase 1 and/or Phase 2 clinical trials. Several vaccines have already advanced into Phase 3 efficacy trials, while others will do so before the end of 2020. Here, we summarize what is known of the antibody and T-cell immunogenicity of these vaccines in NHPs and humans. To the extent possible, we compare how the vaccines have performed, taking into account the use of different assays to assess immunogenicity and inconsistencies in how the resulting data are presented. We also summarize the outcome of SARS-CoV-2 challenge experiments in immunized macaques, while noting variations in the protocols used, including but not limited to the virus challenge doses. Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 7 September 2020 3 Introduction The COVID-19 pandemic rages unabated and may continue to do so until there is a safe, effective and widely used protective vaccine.
[Show full text]
Immunogenicity of a New Gorilla Adenovirus Vaccine Candidate for COVID-19
bioRxiv preprint doi: https://doi.org/10.1101/2020.10.22.349951; this version posted October 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 Stefania Capone1,6, Angelo Raggioli1,6, Michela Gentile1, Simone Battella1, Armin Lahm1, Andrea Sommella1, Alessandra Maria Contino1, Richard A. Urbanowicz2,3,4, Romina Scala1, Federica Barra1, Adriano Leuzzi1, Eleonora Lilli1, Giuseppina Miselli1, Alessia Noto1, Maria Ferraiuolo1, Francesco Talotta1, Theocharis Tsoleridis2,3,4, Concetta Castilletti5, Giulia Matusali5, Francesca Colavita5, Daniele Lapa5, Silvia Meschi5, Maria Capobianchi5, Marco Soriani1, Antonella Folgori1, Jonathan K. Ball2,3,4, Stefano Colloca1 and Alessandra Vitelli1* 1 ReiThera Srl, Rome, Italy 2 School of Life Sciences, The University of Nottingham, UK 3 NIHR Nottingham Biomedical Research Centre, The University of Nottingham, UK 4 Wolfson Centre for Emerging Virus Research, The University of Nottingham, UK 5 National Institute for Infectious Diseases "Lazzaro Spallanzani" IRCCS 6 These authors contributed equally * [email protected] ABSTRACT The COVID-19 pandemic caused by the emergent SARS-CoV-2 coronavirus threatens global public health and there is an urgent need to develop safe and effective vaccines. Here we report the generation and the preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding the pre-fusion stabilized Spike (S) protein of SARS-CoV2. We show that our vaccine candidate, GRAd- COV2, is highly immunogenic both in mice and macaques, eliciting both functional antibodies which neutralize SARS-CoV-2 infection and block Spike protein binding to the ACE2 receptor, and a robust, Th1- dominated cellular response in the periphery and in the lung.
[Show full text]
COVID-19 Vaccine Candidates in Development, Special Focus on Mrna and Viral Vector Platforms Dr
To view an archived recording of this presentation please click the following link: http://pho.adobeconnect.com/pbwjspa1fh9a/ Please scroll down this file to view a copy of the slides from the session. Helpful tips when viewing the recording: • The default presentation format includes showing the “event index”. To close the events index, please click on the following icon and hit “close” • If you prefer to view the presentation in full screen mode, please click on the following icon in the top right hand corner of the share screen PublicHealthOntario.ca 2 COVID-19 Vaccine Candidates in Development, special focus on mRNA and viral vector platforms Dr. Marina Salvadori and Dr. April Killikelly Centre for Immunization and Respiratory Infectious Diseases, PHAC October 1, 2020 Disclosures • None of the presenters at this session have received financial support or in-kind support from a commercial sponsor. • None of the presenters have potential conflicts of interest to declare. 2 OBJECTIVE • Describe the mechanism of action of mRNA, viral vector and protein- based vaccines • Discuss the evidence available for vaccines in development that may be available in Canada if proved safe and effective 3 Global COVID-19 Vaccine Development Landscape: • As of September 24, 2020, 63 clinical trials have been registered for developmental vaccine candidates against COVID-19. • Two anti-SARS-COV-2 vaccine candidates have obtained regulatory authorization to initiate clinical trials in Canada and one vaccine candidate has begun clinical testing in Canada (Medicago). 4 Lead Candidate COVID-19 Vaccine Development Landscape: Protein-based (top box), viral vector based (middle box) and mRNA (bottom box) and technology constitute the majority of the front running COVID-19 vaccine technologies.
[Show full text]
Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis
processes Article Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis Rafael G. Ferreira 1,* , Neal F. Gordon 2, Rick Stock 2 and Demetri Petrides 3 1 Intelligen Brasil, Sao Paulo 01227-200, Brazil 2 BDO USA, LLP, Boston, MA 02110, USA; [email protected] (N.F.G.); [email protected] (R.S.) 3 Intelligen, Inc., Scotch Plains, NJ 07076, USA; [email protected] * Correspondence: [email protected] Abstract: The COVID-19 pandemic has motivated the rapid development of numerous vaccines that have proven effective against SARS-CoV-2. Several of these successful vaccines are based on the adenoviral vector platform. The mass manufacturing of these vaccines poses great challenges, especially in the context of a pandemic where extremely large quantities must be produced quickly at an affordable cost. In this work, two baseline processes for the production of a COVID-19 adenoviral vector vaccine, B1 and P1, were designed, simulated and economically evaluated with the aid of the software SuperPro Designer. B1 used a batch cell culture viral production step, with a viral titer of 5 × 1010 viral particles (VP)/mL in both stainless-steel and disposable equipment. P1 used a perfusion cell culture viral production step, with a viral titer of 1 × 1012 VP/mL in exclusively disposable equipment. Both processes were sized to produce 400 M/yr vaccine doses. P1 led to a smaller cost per dose than B1 ($0.15 vs. $0.23) and required a much smaller capital investment ($126 M vs. $299 M). The media and facility-dependent expenses were found to be the main contributors to the operating cost.
[Show full text]
Protective Zika Vaccines Engineered to Eliminate Enhancement of Dengue Infection Via Immunodominance Switch
ARTICLES https://doi.org/10.1038/s41590-021-00966-6 Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch Lianpan Dai 1,2,3,8 ✉ , Kun Xu3,8, Jinhe Li2,4,8, Qingrui Huang5, Jian Song 1, Yuxuan Han2, Tianyi Zheng2,4, Ping Gao2,4, Xuancheng Lu6, Huabing Yang 5, Kefang Liu7, Qianfeng Xia3, Qihui Wang 1, Yan Chai1, Jianxun Qi 1, Jinghua Yan 5 ✉ and George F. Gao 1,2,4 ✉ Antibody-dependent enhancement (ADE) is an important safety concern for vaccine development against dengue virus (DENV) and its antigenically related Zika virus (ZIKV) because vaccine may prime deleterious antibodies to enhance natural infections. Cross-reactive antibodies targeting the conserved fusion loop epitope (FLE) are known as the main sources of ADE. We design ZIKV immunogens engineered to change the FLE conformation but preserve neutralizing epitopes. Single vaccination conferred sterilizing immunity against ZIKV without ADE of DENV-serotype 1–4 infections and abrogated maternal–neonatal transmis- sion in mice. Unlike the wild-type-based vaccine inducing predominately cross-reactive ADE-prone antibodies, B cell profiling revealed that the engineered vaccines switched immunodominance to dispersed patterns without DENV enhancement. The crystal structure of the engineered immunogen showed the dimeric conformation of the envelope protein with FLE disruption. We provide vaccine candidates that will prevent both ZIKV infection and infection-/vaccination-induced DENV ADE. IKV is a mosquito-borne pathogen belonging to the genus models12,13,19,20. More importantly, a recent study of pediatric cohorts Flavivirus in the family Flaviviridae1. The 2015–2016 ZIKV in Nicaragua clearly shows that previous ZIKV infection enhanced epidemic spread to 84 countries worldwide, including future risk of DENV2 disease and severity, as well as DENV3 sever- Z2,3 21,22 China .
[Show full text]
Prediction of the Supportive Vaccine Type of the Covid-19 for Public Health
Available online at http://scik.org J. Math. Comput. Sci. 11 (2021), No. 5, 5703-5719 https://doi.org/10.28919/jmcs/5738 ISSN: 1927-5307 PREDICTION OF THE SUPPORTIVE VACCINE TYPE OF THE COVID-19 FOR PUBLIC HEALTH NISHANT NAMDEV, ARVIND KUMAR SINHA* Department of Mathematics, National Institute of Technology, Raipur, India Copyright © 2021 the author(s). This is an open access article distributed under the Creative Commons Attribution License,which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract: The novel corona virus SARS-Cov-2 caused the COVID-19 pandemic and mostly deteriorated the respiratory system. This paper aims to predict the supportive vaccine type (RNA, Non-replicating viral vector, DNA, Inactivated, Protein subunit) of COVID-19 for the human being by the rough set's novel process. The Rough set is an approach to identify patterns in uncertainty. The vaccine dataset, vaccine name, number of tested cases, age, randomize, and vaccine types of COVID-19 have been taken to overcome this disaster. By the rough set method, the supportive vaccine pattern is predicted, and it is observed that the vaccine based on RNA is highly supported to the human beings compared to the others. Extensive tests explained the Pfizer vaccine (RNA) is 95% effective, Moderna (mRNA) is 94.1%, while the Oxford/AstraZeneca (Non-replicating) one is 62%. It shows that the efficiency obtained by the rough set is accurate. A data-intensive computer-based analysis is given for the medical system. Furthermore, we present an extended record of sources that will support the scientific bioinformatics society to attain various sorts of a database linked to SARS-CoV-2 and advances to associate with COVID-19 treatment.
[Show full text]
Government of India PIB Press Briefing 8Th December 2020 India: Covid-19 Snapshot (As on 8Th December)
Government of India PIB Press Briefing 8th December 2020 India: Covid-19 Snapshot (As on 8th December) Total cases Active cases Deaths Tests 97.03 lakhs 3.83 lakhs 1.40 lakhs 14.8 crores Case Per Million Contribution Death Per Million Tests Per Million 7,031 3.96% 102 107,836 Case Positivity Case Fatality Rate 6.5% 3.2% 1.45% 1.3% (Overall) (Last 1 week) (Overall) (Last 1 week) Cases per million population – Amongst the lowest in the world 45,000 43,495 40,000 34,514 35,000 30,942 30,000 28,594 25,384 25,000 20,000 17,055 15,000 10,000 7,031 5,000 0 India Russia UK Italy Brazil France USA Source: WHO COVID-19 Dashboard updated 7th December 2020 Deaths per million population – Amongst the lowest in the world 993 1,000 902 900 830 839 842 800 700 600 500 400 298 300 200 102 100 0 India Russia Brazil France USA UK Italy Source: WHO COVID-19 Dashboard updated 7th December 2020 Deteriorating Situation in the World 44k USA 217k SPAIN TURKEY in Early - Dec in End - Nov 77k 32k in Mid - Aug 55k in Mid - April in Early - Nov 10k 5k in Early - April in Mid - April Mar May Jul Sep Nov Mar May Jul Sep Nov Mar May Jul Sep Nov 98k INDIA RUSSIA 28k UNITED KINGDOM 34k in Early - Sep in Early - Dec in Mid - Nov 11k in Early - May 6k in Early - April Mar May Jul Sep Nov Mar May Jul Sep Nov Mar May Jul Sep Nov FRANCE BRAZIL 55k 49k in Early - August 125k in Early - Dec in Mid - Nov 26k in End - April Country Trajectory as on 8th December 2020; Mar May Jul Sep Nov Mar May Jul Sep Nov Source: coronavirus.jhu.edu; India: Active cases continue to decline, now below 4 lakhs 10,03,299 10,00,000 8,12,390 8,00,000 6,97,330 5,61,908 6,00,000 3,73,379 3,83,866 4,00,000 2,00,000 0 Top States/UTs contributing to total active cases Active Cases Maharashtra 76,852 Kerala 59,607 Karnataka 24,786 West Bengal 23,829 Delhi 22,486 These 5 states contribute 54% of total active cases in the country COVID-19 Vaccination “I would like to tell my countrymen that our scientists are dutifully engaged in the laboratories.
[Show full text]
COVID-19 Vaccine Weekly Intel Report
COVID-19 Vaccine Weekly Intel Report Science, trial forecast, production and news analysis April 23rd - Prepared for BIO, DCVMN, IFPMA © 2021 Airfinity Ltd | Private & Confidential. © 2021 Airfinity Ltd | Private & Confidential Over 9 billion doses could be produced this year An analysis of forecasted production of vaccine candidates ForecasteD proDuction 9,889,406,370 8,478,587,508 7,206,503,589 5,982,385,185 4,871,966,540 3,815,817,604 2,870,502,904 2,080,496,478 1,388,902,344 830,218,085 200,715,588 425,929,684 Jan-21 Feb-21 Mar-21 Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21 Nov-21 Dec-21 © 2021 Airfinity Ltd | Private & Confidential 2 Over 9 billion doses could be produced this year An analysis of forecasted production of vaccine candidates split by candidate Ad26COVS1 (J&J) mRNA-1273 (MoDerna) Ad5-nCoV (CanSino) MVC-COV1901 (MeDigen/Dynavax) AZD1222 (University of OxforD/AstraZeneca) NasoVAX (Altimmune) BBIBP-CorV (Beijing/Sinopharm) NVX-CoV2373 (Novavax) BNT162b2 (Pfizer/BioNTech) S-268019 (UMN Pharma) CoronaVac (Sinovac) SCB-2019 (Clover/Dynavax) COVAXIN (Bharat/ICMR/NIV) Sputnik V (Gamaleya Research Institute) CoviVac (Chumakov FeDeral Scientific Center) UB-612 (Covaxx) CVnCoV (Curevac) Vaccine (Anhui Zhifei) 9,889,406,370 EpiVacCorona (VECTOR) Vaccine (MeDicago/GSK) GRAD-COV2 (Reithera/LeukoCare/Univercells ) Vaccine (Sanofi/GSK) 8,478,587,508 INO-4800 (Inovio Pharma) VLA2001 (Valneva/Dynavax) LUNAR-COV19 (Arcturus) ZyCoV-D (ZyDus Cadila) 7,206,503,589 5,982,385,185 4,871,966,540 3,815,817,604 2,870,502,904 2,080,496,478
[Show full text]
Current and Future HPV Vaccines: Promise and Challenges
Current and Future HPV Vaccines: Promise and Challenges 2006 1455 NW Leary Way Seattle, WA 98107-5136 USA Tel: 206.285.3500 Fax: 206.285.6619 www.path.org Copyright © 2006, Program for Appropriate Technology in Health (PATH). All rights reserved. The material in this document may be freely used for educational or noncommercial purposes, provided that the material is accompanied by an acknowledgement line. Contents Abbreviations and acronyms....................................................................................................... 1 Acknowledgments....................................................................................................................... 3 Executive summary..................................................................................................................... 4 Therapeutic vaccines ...............................................................................................................4 Introducing prophylactic HPV vaccines..................................................................................5 I. Introduction ............................................................................................................................ 7 A. HPV-related disease............................................................................................................7 B. Prophylactic and therapeutic vaccine strategies..................................................................9 II. Prophylactic vaccine research ............................................................................................
[Show full text]
Valneva Initiates Phase 3 Clinical Trial for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001
VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France Valneva Initiates Phase 3 Clinical Trial for its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001 Saint-Herblain (France), April 21, 2021 – Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, today announced it has initiated a pivotal Phase 3 clinical trial for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The Phase 3 trial “Cov-Compare”, (VLA2001-301), will compare Valneva’s SARS-CoV-2 vaccine candidate, VLA2001, against AstraZeneca’s conditionally approved vaccine, Vaxzevria1, in a comparative immunogenicity trial. Approximately 4,000 participants will receive two doses of either vaccine. The primary endpoint of Cov- Compare will be to determine the immune response (Geometric Mean Titer (GMT)) of SARS-CoV-2- specific neutralizing antibodies) two weeks after completion of a two-dose immunization schedule administered in a four-week interval. The trial is powered to demonstrate superiority of VLA2001 in terms of GMT ratio (VLA2001/Vaxzevria). The trial will be conducted in the U.K. and is supported by the National Institute for Health Research (NIHR). Adam Finn, Chief investigator for the VLA 2001-301 program, Professor of Paediatrics at the University of Bristol and Consultant at the Bristol Royal Hospital for Children said, “Following very encouraging safety and immune response results from our Phase 1/2 trial, along with my investigator colleagues, I am really looking forward to starting on this important next stage of the clinical development of this important new vaccine.
[Show full text]
Strategy for COVID-19 Vaccination in India: the Country with the Second Highest Population and Number of Cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R
www.nature.com/npjvaccines PERSPECTIVE OPEN Strategy for COVID-19 vaccination in India: the country with the second highest population and number of cases ✉ Velayudhan Mohan Kumar 1, Seithikurippu R. Pandi-Perumal 2 , Ilya Trakht3 and Sadras Panchatcharam Thyagarajan 4 Free vaccination against COVID-19 commenced in India on January 16, 2021, and the government is urging all of its citizens to be immunized, in what is expected to be the largest vaccination program in the world. Out of the eight COVID-19 vaccines that are currently under various stages of clinical trials in India, four were developed in the country. India’s drug regulator has approved restricted emergency use of Covishield (the name employed in India for the Oxford-AstraZeneca vaccine) and Covaxin, the home- grown vaccine produced by Bharat Biotech. Indian manufacturers have stated that they have the capacity to meet the country’s future needs for COVID-19 vaccines. The manpower and cold-chain infrastructure established before the pandemic are sufficient for the initial vaccination of 30 million healthcare workers. The Indian government has taken urgent measures to expand the country’s vaccine manufacturing capacity and has also developed an efficient digital system to address and monitor all the aspects of vaccine administration. npj Vaccines (2021) 6:60 ; https://doi.org/10.1038/s41541-021-00327-2 1234567890():,; INTRODUCTION eight vaccine candidates, currently undergoing clinical trials in A year has passed since the first case of novel coronavirus India, is shown in Table 1 and their technical details are given in 13 infections was detected in China’s Wuhan province.
[Show full text]
Valneva Commences Rolling Submission to MHRA for Its Inactivated, Adjuvanted COVID-19 Vaccine
VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France Valneva Commences Rolling Submission to MHRA for its Inactivated, Adjuvanted COVID-19 Vaccine Saint-Herblain (France), August 23, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on prophylactic vaccines for infectious diseases, today commenced rolling submission, for initial approval of its COVID-19 vaccine candidate, VLA2001, with the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK). VLA2001 is a whole virus, inactivated, adjuvanted vaccine candidate and is the only vaccine candidate of this type currently in clinical trials in Europe. VLA2001 is currently being studied in the UK in a pivotal Phase 3 trial, “Cov-Compare” (VLA2001-301), for which topline results are currently expected early in the fourth quarter 2021. Subject to positive Cov- Compare data and MHRA review, Valneva believes that initial approval could be granted before the end of 2021. In September 2020, Valneva announced a collaboration with the UK Government, which has the option to purchase up to 190 million doses through 2025. So far, the UK Government has ordered 100 million doses for supply in 2021 and 2022. Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, “We are pleased to begin the regulatory review process for our COVID-19 vaccine with the MHRA. Valneva believes that everyone should have access to technology best suited to protect them against this virus. We are working hard to make our vaccine candidate available as soon as possible. We are grateful to the National Institute for Health Research (NIHR), Public Health England (PHE), and other partners for their unstinting support and hard work.” Valneva recently initiated a further Phase 3 clinical trial, VLA2001-304, to generate data in the elderly and as part of the Company’s strategy to evaluate variant-based vaccines.
[Show full text]